CASP1 and myocarditis: Likewise, NLRP3 inhibitors or caspase-1 inhibitors might attenuate myocardial inflammation—experimental IL-37 therapy (a cytokine that broadly suppresses inflammasome activity) dramatically reduced cardiac inflammation and improved survival in CVB3 myocarditis mice, highlighting inflammasome inhibition as a potential strategy (32, 47).